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Apolipoprotein E and clusterin inhibit the early phase of amyloid-β
aggregation in an in vitro model of cerebral amyloid angiopathy
Abstract

Sporadic cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid-β (Aβ) deposition,
which leads to lobar hemorrhage and dementia. Biological molecules affecting the development of CAA have
not been fully characterized. In this study, we performed proteome analysis of biopsied leptomeningeal and
cortical vessels obtained from 6 CAA patients and 5 non-CAA patients who underwent surgery for large lobar
hemorrhages. We found that 6 proteins, including Aβ, apolipoprotein E (apoE), clusterin (CLU), albumin,
complement C4 and vitronectin were significantly upregulated in the vessels of CAA patients as compared to
non-CAA patients. ApoE and CLU were found in all CAA patients. We next examined the effects of apoE and
CLU on the early phase of Aβ aggregation, using a simple yet powerful in vitro model of CAA, which
recapitulates the intramural periarterial drainage pathway model. We found that physiological concentrations
of apoE and CLU delayed the initiation time of amyloid growth kinetics in a concentration-dependent
manner. These data indicate that apoE and CLU may act as extracellular chaperones to inhibit Aβ amyloid
deposition in CAA.
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Abstract
Sporadic cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid-β (Aβ) deposition, which
leads to lobar hemorrhage and dementia. Biological molecules affecting the development of CAA have not been
fully characterized. In this study, we performed proteome analysis of biopsied leptomeningeal and cortical vessels
obtained from 6 CAA patients and 5 non-CAA patients who underwent surgery for large lobar hemorrhages. We
found that 6 proteins, including Aβ, apolipoprotein E (apoE), clusterin (CLU), albumin, complement C4 and
vitronectin were significantly upregulated in the vessels of CAA patients as compared to non-CAA patients. ApoE
and CLU were found in all CAA patients. We next examined the effects of apoE and CLU on the early phase of Aβ
aggregation, using a simple yet powerful in vitro model of CAA, which recapitulates the intramural periarterial
drainage pathway model. We found that physiological concentrations of apoE and CLU delayed the initiation time
of amyloid growth kinetics in a concentration-dependent manner. These data indicate that apoE and CLU may act
as extracellular chaperones to inhibit Aβ amyloid deposition in CAA.
Keywords: Cerebral amyloid angiopathy, Amyloid-β, Proteome analysis, Apolipoprotein E, Clusterin, Intramural
periarterial drainage, Extracellular chaperone

Introduction
Sporadic cerebral amyloid angiopathy (CAA) is characterized by amyloid-β (Aβ) deposition in the cortical and leptomeningeal arteries, which leads to lobar hemorrhage,
infarction, encephalopathies and dementia [40, 41]. Recently, several groups reported that various proteins are deposited with Aβ in the vessel walls of postmortem,
autopsied CAA patients [14, 17, 20]. Apolipoprotein E
(apoE), clusterin (CLU, also called apolipoprotein J. apoJ),
serum amyloid-P component, tissue inhibitor of
metalloproteinases-3, sushi repeat-containing protein 1
(SRPX1) and other proteins are the major Aβ-associated
proteins in the vessel walls of CAA patients. However, the
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effects of these proteins on the development of CAA are
not clear except for SRPX1, which may enhance the cerebrovascular degeneration induced by Aβ [17].
In this study, we first performed proteome analysis of
biopsied leptomeningeal and cortical vessels obtained
from 6 CAA patients and 5 non-CAA patients who underwent surgery for large lobar hemorrhages [18]. We found
that expression of apoE and CLU is significantly increased
in the vessels of acute-onset, symptomatic CAA patients
as compared to non-CAA patients. Next, we examined
the effects of apoE and CLU on the early phase of Aβ aggregation, using a powerful, physiologically relevant in
vitro model of CAA [10]. This model was previously
established to test the hypothesis that intramural periarterial drainage (IPAD) flow carries Aβ to the vascular
basement membrane (BM), which may trap Aβ and induce amyloid fibril formation in vivo [1, 22].

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Materials and methods
Materials

Aβ(1–40) (code 4307-v, trifluoroacetic salt, lyophilized
from dimethyl sulfoxide solution) was purchased from
Peptide Institute Inc. (Osaka, Japan). Human serum albumin (HSA) (code 70024–90-7, A8763) was purchased
from Sigma. Matrigel (Phenol Red free, code 356237)
was purchased from Becton-Dickinson and Co. (NJ,
USA). NHS-activated Sepharose 4 Fast Flow (code 17–
0906-01) was purchased from GE Healthcare UK Ltd.
Recombinant human apolipoprotein E3 (apoE3) (code
010–20261) and apoE4 (code 017–20271) were purchased from Wako (Osaka, Japan). Human CLU was
purified from human serum as described previously [29].

Patients and specimens for proteome analysis

We recently reported the prevalence of CAA in patients
who underwent surgery in our hospital for large lobar
hemorrhages, i.e., supratentorial bleeding expanding
from the cerebral cortex to subcortical white matter
[18]. To diagnose CAA, we examined biopsied cortical
tissues around hematomas with Congo-red and anti-Aβ
staining. The same biopsied tissue was used for a series
of histopathological and immunohistochemical staining
to diagnose CAA and for the subsequent proteome
analysis. We examined a cohort of 24 CAA patients
and 5 non-CAA patients. Of 24 CAA patients, 16 patients (66.7%) had severe (Grade 4) CAA based on the
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pathological grading system for CAA developed by
Greenberg et al. [9].
From this cohort, we selected 6 CAA patients (all Grade
4) and 4 non-CAA patients for which sufficient amounts
of pathological specimens were available for the subsequent proteome analysis (Table 1). To increase the patient
number, we added one additional non-CAA patient who
underwent surgery in our hospital (B-1 in Table 1).
Protein extraction and proteome analysis

Protein extraction and proteome analysis were performed
with liquid chromatography-tandem mass spectrometry
(LC-MS/MS), essentially as described elsewhere [17].
Briefly, 4 μm thick slices of formalin-fixed and
paraffin-embedded brain biopsy samples were placed on
membrane slides (Leica Microsystems, Wetzlar,
Germany). Sections were air-dried and then melted,
deparaffinized, and stained with Congo red combined with
nuclear counterstaining with hematoxylin. In the CAA
group, Congo red-positive leptomeningeal and cortical
vessels, which were identified using the bright-field setting, were isolated via laser capture microdissection
(LCM) (LMD7000; Leica Microsystems, Wetzlar,
Germany) (Table 1), then analysed using nano-flow
reversed-phase LC–MS/MS (LTQ Velos Pro; Thermo
Fisher Scientific). In the non-CAA group, leptomeningeal
and cortical vessels, which were identified using the
bright-field setting, were isolated via LCM. In both groups,
we didn’t discriminate arteries from veins. The relative

Table 1 Profiles of cases of CAA and non-CAA patients analysed by LMD-LC-MS/MS
Number Group Age Sex Lesion of brain
hemorrhage

Amyloid
grading scalea

Hypertension and
medication

Anticoagulants or
antiplatelets

Microbleeding at Patient number in
MRI (T2*)
Table 3 of [18]

A-1

CAA

66

F

R temporoparietal

4

No

No

negative

3

A-2

CAA

80

F

L temporoparietal

4

Yes, medication

No

NA

4

A-3

CAA

79

F

L frontal

4

No

No

NA

5

A-4

CAA

74

F

R frontal

4

Yes, medication

No

positive

6

b

A-5

CAA

71

F

L frontal

4

Yes, medication

No

positive

7

A-6

CAA

63

F

L parietal

4

No

No

negative

12

B-1

nonCAA

83

F

R putamen and
frontal

0

Yes, no medication No

negative

Not included

B-2

nonCAA

67

M

R fronto-parietal

0

Yes, no medication No

negative

25

B-3

nonCAA

75

M

R temporoparietal

0

No

No

NA

26

B-4

nonCAA

61

M

R frontal

0

No

No

negative

28

B-5

nonCAA

68

M

R frontal

0

Yes, medication

No

NA

27

M male, F female, R right, L left, NA not applicable
a
Pathological grading system for CAA by Greenberg SM et al. [9]
b
Self-withdrawal 2 years before onset
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abundances of the identified molecules were obtained
using the normalized spectral abundance factor (NSAF)
[27] (Table 2).
Kinetic analysis of the seeded aggregation of Aβ(1–40)
amyloid fibrils

In this paper, we used only Aβ(1–40) because Aβ(1–40) is
the predominant Aβ species deposited in the vessels of
CAA patients [40, 41]. Aβ(1–40) amyloid fibrils (fAβ(1–
40)) were first formed by incubating 1.0 ml of the reaction
mixture containing 50 μM Aβ(1–40), 50 mM sodium
phosphate, pH 7.5, 100 mM NaCl phosphate buffered saline (PBS), and 0.05% NaN3 at 37 °C for 1 week. Subsequently, a reaction mixture containing 2.5 μg/ml fAβ(1–
40), 5 μM Aβ(1–40), 0–0.5 μM apoE3 or 0–1.0 μM CLU,
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0.3 mg/ml (4.5 μM) HSA, PBS, and 5 μM thioflavin T
(ThT) was incubated at 37 °C without shaking in a 96-well
plate (code HSP9666, Bio Rad, USA) sealed with a sealing
film (code 676070, Greiner Bio-One GmbH, Frickenhausen, Germany). ThT fluorescence was measured every 5
min for 2 h using a Safire2 microplate fluorometer
(TECAN, Austria) with excitation at 445 nm and emission
at 490 nm.
Analysis of the effects of ApoE and CLU on the length of
the lag phase of Aβ(1–40) amyloid aggregation

In this paper, we utilized a previously established powerful in vitro model of CAA [10] to analyse the effects of
apoE and CLU on the length of the lag phase of Aβ(1–
40) amyloid aggregation, essentially as described in [10].

Table 2 Proteins in the cerebral blood vessels of CAA patients vs. non-CAA patients
Non-CAA (n = 5) a

p value*

Accession
number

Protein

CAA (n = 6)a

P02649

Apolipoprotein E

100

0.1259

20

0.0006

0.004

P05067

Amyloid beta A4 protein

100

0.0685

0

ND

0.004

P10909

Clusterin

100

0.039

20

0.0015

0.004

P02768

Serum albumin

100

0.046

100

0.0154

0.017

P08123

Collagen alpha-2(I) chain

100

0.0031

80

0.0019

0.329

P68871

Hemoglobin subunit beta

100

0.1695

100

0.249

0.662

P69905

Hemoglobin subunit alpha

100

0.0778

100

0.0718

0.792

P04004

Vitronectin

83

0.0085

20

0.0004

0.03

P0C0L4

Complement C4-A

83

0.0032

20

0.0001

0.03

P08670

Vimentin

83

0.0207

80

0.0159

0.247

P41222

Prostaglandin-H2 D-isomerase

67

0.013

40

0.0021

0.177

Q15149

Plectin

67

0.0006

40

0.0001

0.177

Q8IYA6

Cytoskeleton-associated protein 2-like

67

0.0147

80

0.006

0.537

P06727

Apolipoprotein A-IV

50

0.0096

0

ND

0.177

% Detection NSAFCAA % Detection NSAFnon-CAA

Q70EL1

Inactive ubiquitin carboxyl-terminal hydrolase 54

50

0.0035

0

ND

0.177

P11047

Laminin subunit gamma-1

50

0.0014

0

ND

0.177

P02042

Hemoglobin subunit delta

50

0.0313

80

0.0735

0.247

Q8N413

Solute carrier family 25 member 45

50

0.0102

20

0.0011

0.329

P35625

Metalloproteinase inhibitor 3

50

0.0084

20

0.0009

0.329

P07437

Tubulin beta chain

50

0.0061

40

0.0018

0.429

P12814

Alpha-actinin-1

50

0.0015

40

0.0005

0.429

P14136

Glial fibrillary acidic protein

50

0.0265

60

0.0116

0.662

Q9BQE3

Tubulin alpha-1C chain

50

0.0051

60

0.0018

0.662

A6NNT2

Putative uncharacterized protein C16orf96

50

0.004

60

0.0011

0.662

P04350

Tubulin beta-4A chain

50

0.0064

80

0.0045

0.792

P98160

Basement membrane-specific heparan sulfate proteoglycan core protein 50

0.0004

60

0.0004

1

Proteins which show the % detection to be ≥50% in CAA patients are listed. % Detection means the relative number of patients positive for each protein in both
CAA and non-CAA patients
ND not detected
*The Mann-Whitney U test was used for comparisons between NSAFCAA and NSAFnon-CAA values
a
Protein abundance values were estimated using NSAF (normalized spectral abundance factor) normalizaiton
Boldface highlights the proteins which were significantly upregulated in the cerebral blood vessels of CAA patients as compared to non-CAA patients
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Briefly, we reconstituted an artificial BM on the surface
of NHS-activated Sepharose 4 Fast Flow beads by conjugating Matrigel to their surface (Fig. 1). Matrigel-coated
beads were then incubated with 5 μM Aβ(1–40), 0.3 mg/
ml (4.5 μM) HSA, PBS, 0.05% NaN3 (PBS-NaN3), 5 μM
ThT, and 0–0.5 μM apoE3/E4 or 0–1.0 μM CLU at 37 °C
in a clear microtiter plate module (Nunc, F8 Immuno
module, Maxisorp, code: 468667) in which the air water
interface was completely removed. The plate was gently
rotated at 1 rpm. As these beads slowly sink from the
top to the bottom of a well, their surfaces are exposed to
the relative countercurrent of the reaction mixture,
which mimics the IPAD flow in vitro.
The ThT-reactive aggregates in the microtiter wells were
visualized with a fluorescence microscope (MVX10, Olympus Corporation, Tokyo, Japan) equipped with CFP filter
sets (excitation 425–445 nm, emission 460–510 nm). Then
the fluorescence images recorded for 1 s with a DP 72
digital camera (Olympus Corporation, Tokyo, Japan). We
chose the first time point at which ThT-reactive aggregates
were detected as the initiation time for fibril growth kinetics. The preceding lag phase is the time during which nuclei, on-pathway oligomers and protofibrils are successively
formed prior to the subsequent rapid fibril growth phase.
In most cases, one observer (Y.E.) mainly determined the
initiation time by visual inspection of recorded images. In
the specific cases of data shown in Figs. 4, 5 and 6, another
observer (R.N.) re-determined the initiation time and similar results were obtained (data not shown).
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To monitor Aβ(1–40) amyloid formation in a conventional way, we also measured the ThT fluorescence with
a Safire2 microplate fluorometer (TECAN, Austria). For
the kinetic analysis, data obtained with a fluorescence
microscope was used because microscopic detection of
fluorescent spots on the Sepharose-beads often preceded
the increase in fluorescence measured by fluorometry by
12 to 24 h (data not shown).
We then measured the duration of the lag phase for
each well using the Kaplan-Meier survival method and the
initiation time of amyloid growth kinetics as the event of
interest (Fig. 2). In this assay, the reaction mixture in
which ThT-reactive aggregates have not yet been detected
is considered as “surviving”. Thus, the survival rate corresponds to the percentage of the reaction mixtures in
which ThT-reactive aggregates have not yet been detected.
The statistical significance was compared by the log rank
test, followed by pair to pair multiple comparisons using
the Holm-Sidak method. For the calculation, we excluded
any wells in which air bubbles emerged before the detection of ThT-reactive aggregates. The survival analysis was
performed with SigmaPlot 12 (Systat Software, Inc. CA).
The differences between the two groups were considered
significant if P values were less than 0.05.

Results
Profiles of CAA and non-CAA patients

Table 1 shows the profiles of the CAA and non-CAA
patients analysed by LCM-LC-MS/MS. The 6 CAA

Fig. 1 Schematic representation of the in vitro model of CAA used in this study. Sepharose 4 Fast Flow beads are highly cross-linked 4% agarose
beads with a mean diameter of 90 μm. The pore sizes of the beads may be similar to the sizes of BM components, resulting in the conjugation of
BM components onto the surface of beads. During the rotation, beads are exposed to the relative countercurrent of the reaction mixture, which
mimics intramural periarterial drainage (IPAD) flow in vitro and enhances the interaction of Aβ with surface-bound BM components leading to Aβ
aggregation. HSA: human serum albumin (modified from Fig. 6 of [10])
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Fig. 2 Kaplan-Meier survival method used to evaluate the duration of the lag phase of Aβ aggregation. The kinetics were analysed by the KaplanMeier survival method using the initiation time of amyloid growth kinetics as the event of interest. Aβ(1–40) was incubated with Matrigel-coated
Sepharose beads as described in Materials and Methods. The appearance of ThT-reactive aggregates was monitored with a fluorescence
microscope. The first time at which ThT-reactive aggregates were detected was set as the initiation time of amyloid growth. When ThT-reactive
aggregates are detected in 1 well of 5, the “survival rate” is recorded as having decreased from 1.0 to 0.8. Similarly, if ThT-reactive aggregates are
then detected in 1 of the remaining 4 wells, then the “survival rate” is recorded as having decreased from 0.8 to 0.6. Thus, the slower the kinetics
of early phase Aβ aggregation, the more time is required to reach a “survival” value of zero. This model was used to evaluate the concentrationdependent effects of apoE and CLU on the kinetics of early phase Aβ aggregation

patients were from 63 to 80 years old (mean ± SD 72.2
± 6.9). Compatible with the female predominance in
CAA patients [41], all 6 patients were female and had
grade 4 CAA. Three of the 6 patients had hypertension
and took antihypertensive agents. No patients took
anticoagulant or antiplatelet drugs. Two patients were
positive for strictly lobar microbleeding as evaluated by
T2*-weighted magnetic resonance imaging (MRI). The
ages of the 5 non-CAA patients were from 61 to 83
years old (mean ± SD 70.8 ± 8.4). Four patients were
male, and 1 patient was female. We found no female
predominance in non-CAA patients. Three of the 5 patients had hypertension and only 1 took antihypertensive agents. Thus, it is reasonable to consider that for
these 3 patients, the etiology of hemorrhage may be
hypertension. As for the remaining 2 patients, although
we excluded CAA as an etiology of hemorrhage, we did
not definitely identify the etiology of hemorrhage. No
patients took anticoagulant or antiplatelet drugs. No
patients were positive for microbleeding as evaluated
by T2*-weighted MRI.
Proteome analysis

As shown in Table 2, 6 proteins, including Aβ, apoE,
CLU, albumin, complement C4 and vitronectin were significantly upregulated in the cerebral blood vessels of
CAA patients as compared to non-CAA patients. Aβ
was found only in CAA patients. Albumin was found in
all patients of CAA and non-CAA groups. ApoE and

CLU were found in all patients of the CAA group but
were found in only 1 patient of the non-CAA group
(20%). Both apoE and CLU are representative amyloid
signature proteins [2]. Thus, in the following study, we
analysed the effects of apoE and CLU on Aβ amyloid
formation in two different in vitro systems.
The effects of apoE and CLU on the seeded aggregation
of Aβ(1–40) amyloid fibrils

We first used the conventional in vitro experimental system with an air-water interface to examine the effects of
apoE and CLU on the seeded aggregation of Aβ(1–40)
amyloid. In the absence of apoE and CLU, ThT fluorescence increased rapidly with no lag time to reach a plateau at around 2 h after initiation of the reaction (Fig. 3),
consistent with the first-order kinetic model of amyloid
fibril growth in vitro [25]. As shown in Fig. 3, both apoE
and CLU concentration-dependently inhibited the formation of Aβ amyloid in this system.
The effects of apoE and CLU on the duration of the lag
phase of Aβ aggregation in an in vitro model of CAA

As shown in Fig. 4, apoE3 delayed the initiation time of fibril growth kinetics in a concentration-dependent manner,
indicating that apoE3 inhibited early phase Aβ aggregation.
Importantly, apoE3 significantly inhibited the early phase
aggregation of Aβ when at a concentration that is physiological in the cerebrospinal fluid (CSF) (1.8–4.0 μg/ml or
0.05–0.12 μM) [28]. CLU also concentration-dependently
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A

B

Fig. 3 Effects of apoE and CLU on the seeded aggregation of fAβ(1–40) in vitro. a The reaction mixture containing 2.5 μg/ml fAβ(1–40), 5 μM
Aβ(1–40), 0 (●), 0.05 (○), 0.1 (■), 0.2 (□), 0.5 μM (▲) apoE3, 0.3 mg/ml HSA, PBS, and 5 μM ThT was incubated at 37 °C without shaking in a 96-well
plate. b The reaction mixture containing 2.5 μg/ml fAβ(1–40), 5 μM Aβ(1–40), 0 (●), 0.05 (○), 0.25 (■), 0.5 (□), 1.0 μM (▲) CLU, 0.3 mg/ml HSA, PBS,
and 5 μM ThT was incubated at 37 °C without shaking in a 96-well plate. ThT fluorescence was monitored as described in Materials and Methods.
Points and bars represent mean + S.D. of 6 replicates. This data is representative of three independent experiments

delayed the initiation time of fibril growth kinetics (Fig. 5),
significantly inhibiting the early phase of Aβ aggregation
when at a concentration that is physiological in CSF (3.5–
5.7 μg/ml or 0.07–0.11 μM) [33]. As shown in Fig. 6, the
same concentrations of apoE3 and E4 exhibited no significant isoform-dependent difference in their ability to inhibit
the early phase aggregation of Aβ.
We previously reported that under these same experimental conditions, 0.1–1.0 mg/ml (1.5–15.1 μM) HSA
has no significant effect on the early phase of Aβ aggregation [10]. Thus, we conclude that apoE and CLU specifically and concentration-dependently inhibit the early
phase of Aβ aggregation.

Discussion
In this study, we first performed proteome analysis of
the Aβ-deposited leptomeningeal and cortical vessels
(Tables 1 and 2). To the best of our knowledge, this is
the first report of the proteome analysis of vessels biopsied from living symptomatic, clinical CAA patients. In

previously published reports, proteome analysis was performed with leptomeningeal vessels obtained from postmortem, autopsied cases, in which Aβ deposition was
histopathologically confirmed [14, 17, 20]. Although
CAA is known to be more severe in posterior brain regions compared to anterior brain regions [41] and postmortem proteome analysis was performed using the
vessels derived from occipital lobes [14, 17, 20], frontal
lobes were involved in 3 CAA patients and parietal and
temporal lobes were involved in other 3 CAA patients
(Table 1). This difference in the brain regions from
which the vessels were obtained may affect the results of
proteome analysis (Table 2 vs. [14, 17, 20]). For example,
this may explain why we found no significant upregulation of tissue inhibitor of metalloproteinases-3 (Table 2),
in contrast to the finding of Manousopoulou et al.
[20]. Additionally, the discrepancy in male/female ratio between CAA and non-CAA patients (male/female: 0/6 and 4/1, respectively) may also affect the
results of our proteome analysis. Both apoE and CLU
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Air
No apoE3

Fig. 4 Effect of apoE3 on the kinetics of early phase aggregation of Aβ(1–40). The reaction mixture containing 5 μM Aβ(1–40), 10 μl suspensions
of Matrigel-coated beads, 0.3 mg/ml HSA, PBS-NaN3, 5 μM ThT, and 0 to 0.5 μM apoE3 was incubated at 37 °C with rotation at 1 rpm in the
absence of an air-water interface (30 replicate wells in each case). As a positive control, the reaction mixture containing 5 μM Aβ(1–40), 0.3 mg/ml
HSA, PBS-NaN3, and 5 μM ThT was also incubated at 37 °C with rotation at 1 rpm in the presence of an air-water interface (12 replicate wells) (Air).
The kinetics of early phase aggregation was analysed by the Kaplan-Meier survival method using the initiation time of fibril growth kinetics as the
event of interest (see Fig. 2). The P value was less than 0.05 between all combinations. This data is representative of three independent
experiments

are representative signature proteins in various types
of systemic amyloidosis [2]. Thus, it is worth noting
that apoE and CLU are representative Aβ-associated
proteins in the vessel walls of clinical CAA cases
(Table 2), as well as in those of pathological CAA
cases [14, 17, 20].

Carare and coworkers proposed the IPAD pathway
model [1, 22, 34]. This model constitutes that instead of
the conventional lymphatics, interstitial fluid and solutes
are drained from the brain parenchyma to cervical
lymph nodes along BMs in the walls of cerebral capillaries and tunica media of leptomeningeal arteries.

Air
No CLU

Fig. 5 Effect of CLU on the kinetics of early phase aggregation of Aβ(1–40). The reaction mixture containing 5 μM Aβ(1–40), 10 μl suspensions of
Matrigel-coated beads, 0.3 mg/ml HSA, PBS-NaN3, 5 μM ThT, and 0 to 1.0 μM CLU was incubated at 37 °C with rotation at 1 rpm in the absence of
an air-water interface (18 replicate wells in each case). As a positive control, the reaction mixture containing 5 μM Aβ(1–40), 0.3 mg/ml HSA, PBSNaN3, and 5 μM ThT was also incubated at 37 °C with rotation at 1 rpm in the presence of an air-water interface (18 replicate wells) (Air). The
kinetics of early phase aggregation was analysed by the Kaplan-Meier survival method using the initiation time of fibril growth kinetics as the
event of interest (see Fig. 2). The P value was less than 0.05 between all combinations except for between 0.25 and 0.5 μM CLU. This data is
representative of three independent experiments
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Air
No apoE3/4

Fig. 6 Comparison of the effect of apoE3 with apoE4 on the kinetics of early-phase Aβ(1–40) aggregation. The reaction mixture containing 5 μM
Aβ(1–40), 10 μl suspensions of Matrigel-coated beads, 0.3 mg/ml HSA, PBS-NaN3, 5 μM ThT, and 0 to 0.2 μM apoE3 or apoE4 was incubated at 37 °C
with rotation at 1 rpm in the absence of an air-water interface (18 replicate wells in each case). As a positive control, the reaction mixture containing
5 μM Aβ(1–40), 0.3 mg/ml HSA, PBS-NaN3, and 5 μM ThT was also incubated at 37 °C with rotation at 1 rpm in the presence of an air-water interface
(18 replicate wells) (Air). The kinetics of early phase aggregation was analysed by the Kaplan-Meier survival method using the initiation time of fibril
growth kinetics as the event of interest (see Fig. 2). The P value was less than 0.05 for all pair-wise comparisons except those between apoE3 and
apoE4 when both were at either 0.05 μM or 0.2 μM. This data is representative of three independent experiments

Through this pathway, Aβ peptides, especially Aβ(1–40)
produced by cortical neurons are carried away from the
brain parenchyma [1, 22]. Reduced Aβ trafficking
through this pathway may result in the aggregation of
Aβ amyloid in the cerebrovascular BMs, leading to the
manifestation of pathological as well as clinical CAA
[41]. However, the driving mechanisms of this pathway
and the molecules affecting the trafficking and aggregation of Aβ in this pathway are not fully understood [41,
43]. We previously established a simple yet powerful in
vitro model of CAA, which recapitulates the IPAD flow
draining Aβ and other solutes, as well as the vascular
BM as a scaffold for Aβ aggregation in vitro [10]. To the
best of our knowledge, this is the first, and the only in
vitro system which recapitulates the pathogenesis of
CAA in a physiologically relevant manner (Fig. 1). First,
we completely removed the air-water interface, which is
a hydrophobic-hydrophilic interface that potently induces protein denaturation and amyloid formation [21].
Complete removal of the air-water interface makes it
possible to detect weak effects of BM molecules on the
induction of amyloid formation in vitro. Second, we reduced Aβ concentration as low as possible (5 μM) to inhibit the spontaneous aggregation of Aβ in the reaction
mixture. We also added HSA (4.5 μM) to mimic the CSF
environment. Finally, we reproduced the IPAD flow in
vitro by gently rotating the plate at 1 rpm. As
Matrigel-coated beads slowly sink from the top to the
bottom of a well, their surfaces are exposed to the relative countercurrent of the reaction mixture to induce

the interaction of Aβ with BM molecules. Using this
model, we have demonstrated that apoE and CLU inhibit
the early phase aggregation of Aβ in vitro (Figs. 4 and 5).
Although apoE is considered as a key player in the
pathogenesis of Alzheimer’s disease (AD) and CAA [16,
32], the effects of apoE on the aggregation of Aβ in vitro
and in vivo are controversial. While some groups reported that apoE accelerates Aβ fibril formation in vitro
[31, 35], we and other groups reported that apoE inhibits
Aβ aggregation in vitro [6, 8, 15, 24, 37]. These opposite
effects may be partly due to the difference in the concentrations of Aβ used in each experiment. We previously reported that apoE may inhibit or enhance Aβ
amyloid fibril formation in a concentration-dependent
manner [24]. When 50 μM Aβ(1–40) was incubated with
50–500 nM apoE, apoE dose-dependently inhibited Aβ
amyloid fibril formation. In contrast, when 300 μM
Aβ(1–40) was incubated with 3 μM apoE, apoE slightly
enhanced Aβ aggregation. Similarly, while some groups
reported that apoE promotes Aβ amyloid deposition in
vivo [12], other groups showed that apoE delays Aβ
amyloid deposition in vivo [4, 7, 13, 15, 32]. LaDu and
coworkers produced EFAD mice, which are a tractable
familial AD-transgenic (FAD-Tg) mouse model expressing human APOE rather than mouse APOE [32]. Consistent with our data (Fig. 4), they showed that
introduction of human APOE to EFAD mice delays
extracellular Aβ accumulation (not only plaque deposition but also CAA) from ~ 2 to 6 months compared
with the control 5xFAD mice expressing mouse APOE
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[32]. They suggested that the mouse apoE is structurally
and functionally distinct from human apoE.
The pathogenesis of AD and CAA is affected by apoE
isoform-dependently [16, 32]. Robust data confirmed
that ε4 allele of APOE is not only the risk factor of AD
but also that of nonhemorrhagic-type CAA [3, 16, 32,
40]. In contrast, while the ε2 allele of APOE is protective
for the manifestation of AD, it is a risk factor of
hemorrhagic-type CAA [3, 16, 32, 40]. Tai et al. reported
that the ability of human APOE to delay the extracellular
Aβ accumulation in EFAD mice was in the order of
5xFAD < E4FAD < E3FAD ≤ E2FAD [32]. Consistent with
this in vivo observation, Hori et al. reported that the in
vitro conversion of Aβ protofibrils to fibrils progressed
more slowly upon co-incubation with apoE2 or apoE3 as
compared to the case with apoE4 [15]. In contrast, we
found that the inhibitory effect of apoE3 on the kinetics
of early phase Aβ aggregation was not significantly different from that of apoE4 (Fig. 6). It is hypothesized that
apoE affects the pathogenesis of AD and CAA through a
variety of mechanisms, including the effects on Aβ aggregation, Aβ transport and clearance from the interstitial/cerebrospinal fluid, and cellular metabolism of Aβ
[16]. Thus, the linkage of ε4 allele of APOE to the manifestation of nonhemorrhagic-type CAA might result
from mechanisms other than the direct effects of apoE
on Aβ aggregation. Future studies are eagerly awaited to
resolve this issue.
The pathogenesis of AD and CAA is affected by CLU
[11, 36, 38]. Wilson and coworkers reported that CLU inhibits Aβ aggregation in vitro [26, 39, 42]. Consistent with
our data (Fig. 5), Yerbury et al. reported that CLU significantly inhibits Aβ amyloid fibril formation at a molar ratio
of CLU:Aβ =1:100 [42]. The effects of CLU on the aggregation of Aβ in vivo are controversial. While DeMattos et al.
reported that CLU promotes amyloid plaque formation in
vivo [5], Qi et al. reported that CLU reduces Aβ plaques as
well as the severity of CAA in vivo [30]. Interestingly,
DeMattos et al. reported that apoE−/−/Clu−/− PDAPP mice
had both earlier onset and marked increase of Aβ deposition, suggesting that apoE and CLU cooperatively lower
the Aβ level and suppress deposition [4]. Importantly, Wojtas et al. found a marked decrease in cortical plaque deposition but an equally striking increase in CAA in the brains
of APP/PS1;Clu−/− mice as compared to Clu+/+ mice. They
proposed that CLU facilitates Aβ clearance along the IPAD
pathway by preventing binding of Aβ to cerebrovascular
BMs [36]. This model is consistent with our data indicating
that CLU acts as an extracellular chaperone to prevent the
manifestation of CAA.
Finally, we consider how apoE and CLU inhibit amyloid formation in vitro. Based on a nucleation-dependent
polymerization model [19, 23], we confirmed that apoE
and CLU inhibit the early phase of Aβ aggregation
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(Figs. 4 and 5) as well as the seeded aggregation of
Aβ amyloid fibrils (Fig. 3). Hori et al. reported that
apoE interacts with Aβ protofibrils in the order of
apoE2 = E3 > E4, leading to the inhibition of the conversion of Aβ protofibrils to fibrils [15]. Narayan et
al. reported that CLU binds Aβ oligomers formed
during the aggregation of Aβ monomers, thereby
inhibiting the further growth of these oligomers into
mature amyloid fibrils [26]. These reports may indicate
that apoE and CLU interact with Aβ nuclei/on-pathway
oligomers formed on the Matrigel-coated beads, leading
to the inhibition of the successive aggregation of these
species into amyloid fibrils (Figs. 4 and 5). Additionally,
we previously reported that, like CLU, apoE inhibits the in
vitro growth of Aβ amyloid fibrils by binding and sequestering Aβ monomers [24] (Fig. 3).

Conclusions
We performed proteome analysis with the vessels biopsied from symptomatic, clinical CAA patients and confirmed that the expression of both apoE and CLU are
significantly increased in the vessels of CAA patients as
compared to non-CAA patients. Next, we used a unique
in vitro model of CAA to confirm that apoE and CLU
specifically inhibit the early phase of Aβ aggregation on
the surface of BM-coated beads. The interaction of Aβ
with vascular BMs may be a promising therapeutic target for CAA. Future studies are essential to develop the
therapeutics for CAA.
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